IKKβ-IN-5 是一种具有口服活性和选择性的 IKKβ 抑制剂(IC50 值为 7.5 nM),可直接抑制 IKKβ 磷酸化,从而减弱 NF κB 介导的炎症与生存信号并促进自噬 (autophagy) 流,其对 IKKβ 相较于同源激酶 IKKα 展现出 6 倍的选择性,并通过诱导 G₂/M 期细胞周期阻滞和激活自噬 (autophagy) 的双重机制,即使在体外炎症刺激条件下亦发挥强效的抗增殖作用,同时在体内表现出良好的药代动力学特性并抑制肿瘤生长,可用于结直肠癌及其他潜在炎症驱动型恶性肿瘤的相关研究。
IKKβ-IN-5
产品编号: MS-G05462 分子式: C23H24FN7 分子量: 417.48
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

IKKβ-IN-5 是一种具有口服活性和选择性的 IKKβ 抑制剂(IC50 值为 7.5 nM),可直接抑制 IKKβ 磷酸化,从而减弱 NF κB 介导的炎症与生存信号并促进自噬 (autophagy) 流,其对 IKKβ 相较于同源激酶 IKKα 展现出 6 倍的选择性,并通过诱导 G₂/M 期细胞周期阻滞和激活自噬 (autophagy) 的双重机制,即使在体外炎症刺激条件下亦发挥强效的抗增殖作用,同时在体内表现出良好的药代动力学特性并抑制肿瘤生长,可用于结直肠癌及其他潜在炎症驱动型恶性肿瘤的相关研究。

生物实验数据

生物活性 IKKβ-IN-5 is an orally active and selective IKKβ inhibitor with an IC50 value of 7.5 nM that directly inhibits IKKβ phosphorylation, thereby attenuating NF κB-mediated inflammatory and survival signaling while promoting autophagic (autophagy) flux, exhibits 6-fold selectivity for IKKβ over the homologous kinase IKKα, exerts potent antiproliferative effects through a dual mechanism of inducing G₂/M cell cycle arrest and activating autophagy (autophagy) even under in vitro inflammatory stimulation conditions, demonstrates favorable pharmacokinetic properties and inhibits tumor growth in vivo, and can be used for research on colorectal cancer and other potential inflammation-driven malignancies.
IC50 & Target

IKK-β

7.5 nM (IC50)

体外研究
(In Vitro)

IKKβ-IN-5 (compound LP46) (0-2 μM, 48 小时) 在 RKO 和 HCT116 细胞中表现出强效抗增殖活性且在 NCM460 细胞中具有低毒性。
IKKβ-IN-5 (0.75-3.0 μM, 48 小时) 通过直接抑制 IKKβ 的磷酸化,影响 RKO 和 HCT116 细胞中 IKKβ 磷酸化及其下游靶点 IκBα 的蛋白表达。
IKKβ-IN-5 (0.75-3.0 μM, 7 天) 在 RKO 和 HCT116 细胞中具有长期抗增殖效应。
IKKβ-IN-5 (0.75-3.0 μM, 48 小时) 即使存在炎症刺激,仍通过双重机制 (包括诱导 G2/M 期细胞周期阻滞和激活自噬) 发挥抗增殖作用,并能够阻断 NF-κB 通路激活,从而抑制 RKO 和 HCT116 细胞中的下游炎症反应。
IKKΒ-IN-5 (3 μM, 48 小时) 在 IKKβ 敲低或过表达的结直肠癌细胞中,能直接抵消 IKKβ 介导的促炎和抗自噬效应。

Cell Viability Assay

Cell Line: HCT116, RKO, and NCM460 cells
Concentration: 0, 0.4 0.8, 1.2, 1.6 and 2.0 μM
Incubation Time: 48 h
Result: Exhibited potent inhibitory activity, with IC50 values of 3.94 μM for RKO and 2.59 μM for HCT116.
Showed significantly lower toxicity in NCM460 cells, with an IC50 of 21.25 μM.

Western Blot Analysis

Cell Line: RKO and HCT116 cells
Concentration: 0.75, 1.5, and 3 μM
Incubation Time: 48 h
Result: Significantly reduced phosphorylation of both IKKβ and IκBα in a dose-dependent manner.
Induced greater inhibition of IKKβ phosphorylation.
Had no significant impact on either the expression or phosphorylation of TAK1 or MAP3K1.

Cell Proliferation Assay

Cell Line: RKO and HCT116 cells
Concentration: 0.75, 1.5, and 3 μM
Incubation Time: 7 days
Result: Observed Dose-dependent suppression of colony formation.
Demonstrated superior efficacy at the highest dose.

Cell Cycle Analysis

Cell Line: RKO and HCT116 cells
Concentration: 0.75, 1.5, and 3 μM
Incubation Time: 48 h
Result: Revealed a significant accumulation of RKO and HCT116 cells in the G2/M phase.

Cell Proliferation Assay

Cell Line: RKO and HCT116 cells
Concentration: 0.75, 1.5, and 3 μM
Incubation Time: 48 h
Result: Significantly inhibited DNA synthesis in both RKO and HCT116 cells.

Western Blot Analysis

Cell Line: RKO and HCT116 cells
Concentration: 0.75, 1.5, and 3 μM
Incubation Time: 48 h
Result: Dose-dependently increased expression levels of key autophagy-related markers, Beclin1 and LC3A/B both markers in RKO and HCT116 cells.
Enhanced expression of Beclin1 and LC3A/ B in these cells in RKO and HCT116 cells with TNF-α (MS-C61116).
Reduced p65 expression and inhibited its nuclear translocation in a dose-dependent manner.

RT-PCR

Cell Line: RKO and HCT116 cells
Concentration: 0.75, 1.5, and 3 μM
Incubation Time: 48 h
Result: Significantly down regulated the expression of TNF-α, IL-6, and IL-1β in a dose dependent manner.

Western Blot Analysis

Cell Line: IKKβ knockdown CRC cells or IKKβ overexpression CRC cells
Concentration: 3 μM
Incubation Time: 48 h
Result: Reduced the phosphorylation levels of both IκBα and p65, while concurrently increasing the expression of key autophagy markers, Beclin1 and LC3A/B and exhibited superior efficacy in inhibiting IKKβ phosphorylation and suppressing NF-κB signaling upon TNF-α stimulation in IKKβ knockdown cells.
Increased p-IκBα and p-p65 levels and reduced Beclin1 and LC3A/B expression upon TNF-α stimulation in overexpression of IKKβ cells.
Decreased NF-κB phosphorylation and restoration of autophagy-related protein levels, even under TNF-α stimulation and IKKβ-overexpressing conditions.

Cell Viability Assay

Cell Line: HCT116, RKO, and NCM460 cells
Concentration: 0, 0.4 0.8, 1.2, 1.6 and 2.0 μM
Incubation Time: 48 h
Result: Exhibited potent inhibitory activity, with IC50 values of 3.94 μM for RKO and 2.59 μM for HCT116.
Showed significantly lower toxicity in NCM460 cells, with an IC50 of 21.25 μM.

化学信息

分子量 417.48
分子式 C23H24FN7

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础